Literature DB >> 15931340

Mechanisms of regression.

Dirk M Elston.   

Abstract

Mesh:

Year:  2004        PMID: 15931340      PMCID: PMC1069076          DOI: 10.3121/cmr.2.2.85

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


× No keyword cloud information.
  37 in total

1.  Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials.

Authors:  Joseph A Sparano; Robert Gray; Bruce Giantonio; Peter O'Dwyer; Robert L Comis
Journal:  Clin Cancer Res       Date:  2004-02-15       Impact factor: 12.531

2.  Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma.

Authors:  A Patel; G M Halliday; B E Cooke; R S Barnetson
Journal:  Br J Dermatol       Date:  1994-12       Impact factor: 9.302

3.  Characterization of the mononuclear infiltrate involved in regression of halo nevi.

Authors:  R Akasu; L From; H J Kahn
Journal:  J Cutan Pathol       Date:  1994-08       Impact factor: 1.587

4.  Halo congenital nevus undergoing spontaneous regression. Involvement of T-cell immunity in involution and presence of circulating anti-nevus cell IgM antibodies.

Authors:  Y Tokura; K Yamanaka; H Wakita; S Kurokawa; D Horiguchi; A Usui; S Sayama; M Takigawa
Journal:  Arch Dermatol       Date:  1994-08

5.  Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination.

Authors:  L Adam; M Crépin; L Isräel
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

Review 6.  The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma.

Authors:  R T Prehn
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

7.  Multiple myeloma regression mediated by bruceantin.

Authors:  Muriel Cuendet; Konstantin Christov; Daniel D Lantvit; Yunfan Deng; Samad Hedayat; Lawrence Helson; James D McChesney; John M Pezzuto
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition.

Authors:  C Stanwell; T R Burke; S H Yuspa
Journal:  Cancer Res       Date:  1995-11-01       Impact factor: 12.701

9.  Induction of differentiation of myeloid leukemic cells by busulphan: in vivo and in vitro observations.

Authors:  J Michaeli; E Fibach; E A Rachmilewitz
Journal:  Leuk Lymphoma       Date:  1993-10

10.  Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.

Authors:  H Modjtahedi; S Eccles; J Sandle; G Box; J Titley; C Dean
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

View more
  4 in total

1.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

2.  Spontaneous regression of residual low-grade cerebellar pilocytic astrocytomas in children.

Authors:  Roxana S Gunny; Richard D Hayward; Kim P Phipps; Brian N Harding; Dawn E Saunders
Journal:  Pediatr Radiol       Date:  2005-07-27

Review 3.  Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology.

Authors:  Xixi Dou; Pingzhen Tong; Hai Huang; Lucas Zellmer; Yan He; Qingwen Jia; Daizhou Zhang; Jiang Peng; Chenguang Wang; Ningzhi Xu; Dezhong Joshua Liao
Journal:  J Cancer       Date:  2020-03-04       Impact factor: 4.207

4.  Metastatic papillary thyroid carcinoma with no primary tumor in the thyroid gland: a case report and review of literature.

Authors:  Daxue Li; Jiazhen Li; Jing Zhou; Qian Xiao; Han Gao
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.